(Q36099427)

12 August 2017

1 reference

title

Inhibitors of the mammalian target of rapamycin (English)

1 reference

12 August 2017

Janet E Dancey

1

1 reference

PubMed ID

15833062

12 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

1 reference

12 August 2017

14

1 reference

12 August 2017

313-328

1 reference

12 August 2017

3

1 reference

Targeting mTOR signaling for cancer therapy

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Rheb fills a GAP between TSC and TOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Tuberous sclerosis genes regulate cellular 14-3-3 protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

A signaling pathway to translational control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Signaling control of mRNA translation in cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Does the ribosome translate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Lost in translation: dysregulation of cap-dependent translation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Raptor, a binding partner of target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Hypoxia-inducible factor 1alpha and 1beta proteins share common signaling pathways in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Mechanisms of resistance to rapamycins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Rapamycins: mechanism of action and cellular resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Determinants of rapamycin sensitivity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Critical role of T-loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Dysregulation of the TSC-mTOR pathway in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Life, death and E2F: linking proliferation control and DNA damage signaling via E2F1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

mTOR inhibitors: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Interstitial pneumonitis associated with sirolimus (rapamycin) therapy after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Rituximab and rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.313

10.1517/13543784.14.3.313

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15833062